公开(公告)号：US20210047333A1

公开(公告)日：2021-02-18

申请号：US17007412

申请日：2020-08-31

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Nadia AHMAD ,  Dean BOYALL ,  Jean-Damien CHARRIER ,  Chris DAVIS ,  Rebecca DAVIS ,  Steven DURRANT ,  Gorka ETXEBARRIA I JARDI ,  Damien FRAYSSE ,  Juan-Miguel JIMENEZ ,  David KAY ,  Ronald KNEGTEL ,  Donald MIDDLETON ,  Michael O'DONNELL ,  Maninder PANESAR ,  Francoise PIERARD, Marie ,  Joanne PINDER ,  David SHAW ,  Pierre-Henri STORCK ,  John STUDLEY ,  Heather TWIN

IPC: C07D487/04 ,  C07D453/02 ,  C07D471/08 ,  C07D487/08 ,  C07D491/107 ,  C07D498/04 ,  C07D498/10

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.
The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein.
Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

公开(公告)号：US20230271963A1

公开(公告)日：2023-08-31

申请号：US17847938

申请日：2022-06-23

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Nadia AHMAD ,  Dean BOYALL ,  Jean-Damien CHARRIER ,  Chris DAVIS ,  Rebecca DAVIS ,  Steven DURRANT ,  Gorka ETXEBARRIA I JARDI ,  Damien FRAYSSE ,  Juan-Miguel JIMENEZ ,  David KAY ,  Ronald KNEGTEL ,  Donald MIDDLETON ,  Michael O'DONNELL ,  Maninder PANESAR ,  Francoise PIERARD ,  Joanne PINDER ,  David SHAW ,  Pierre-Henri STORCK ,  John STUDLEY ,  Heather TWIN

IPC: C07D487/04 ,  C07D453/02 ,  C07D471/08 ,  C07D487/08 ,  C07D491/107 ,  C07D498/04 ,  C07D498/10

CPC classification number: C07D487/04 ,  C07D453/02 ,  C07D471/08 ,  C07D487/08 ,  C07D491/107 ,  C07D498/04 ,  C07D498/10

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.
The compounds of this invention have formula I:




or a pharmaceutically acceptable salt, wherein the variables are as devined herein.
Moreover, The compounds of this invention have formula I-A:




or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

公开(公告)号：US20190016671A1

公开(公告)日：2019-01-17

申请号：US16032799

申请日：2018-07-11

Applicant: VERTEX PHARMACEUTICALS INCORPORATED

Inventor： Nadia AHMAD ,  Corey ANDERSON ,  Vijayalaksmi ARUMUGAM ,  Iuliana Luci ASGIAN ,  Joanne Louise CAMP ,  Lev Tyler Dewey FANNING ,  Sara Sabina HADIDA RUAH ,  Dennis HURLEY ,  Yvonne SCHMIDT ,  David SHAW ,  Urvi Jagdishbhai SHETH ,  Stephen Andrew THOMSON

IPC: C07C235/64 ,  C07D213/81 ,  C07D213/89 ,  C07D239/34 ,  C07D317/46 ,  C07D405/12 ,  C07D213/69 ,  C07D213/82 ,  C07D307/79

Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.